Data presented by Sylvester Comprehensive Cancer Center researchers, Trent Wang, DO, MPH and Antonio M. Jimenez Jimenez, MD, MSc, at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.